Diaceutics PLC will hold an investor presentation in Dublin on Tuesday, 29 October 2019. Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects.
HBAN announces that Bluedrop Medical, a Galway based Medical device start up, has secured €3.7M in funding to help manage one of the most devastating complications of diabetes – the diabetic foot. An initial seed investment of €1.2M was led by HBAN’s MedTech Syndicate - which itself invested €340K in the seed round. Enterprise Ireland and the Western Development Commission also invested in the funding round along with other members of the investment community. A €2.5M grant was awarded through the European Innovation Council.
HBAN investors have contributed towards €4 million in additional financing that has been secured by CroíValve, a high potential start-up (HPSU) supported by Enterprise Ireland developing a treatment for tricuspid regurgitation (TR). This is an issue affecting over half-a-million people every year in the US and EU alone, for which there is currently no suitable solution. The financing includes €2.5 million from the European Union under their Horizon 2020 SME Instrument grant and €1.5 million from Broadview Ventures and current investors (HBAN MedTech and Irrus Syndicates, Atlantic Bridge University Fund and SOSV Ventures). The funding will accelerate the development of the company’s novel technology into First in Human studies.